Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

British Journal of Psychiatry

Volumn 178, Issue MARCH., 2001, Pages 234-241

  Thase, M E ^a   Entsuah, A R ^a   Rudolph, R L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; NORADRENALIN; PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0035111499     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.178.3.234     Document Type: Article

References (44)

1. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression
2. Practice guideline for major depressive disorder in adults
3. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants
4. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia
5. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression
6. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
7. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression
8. Medication versus cognitive behavior therapy for severely depressed outpatients: Meta-analysis of four randomized comparisons
9. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients
10. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
11. A molecular and cellular theory of depression
12. Systematic review and guide to selection of selective serotonin reuptake inhibitors
13. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression
14. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence
15. A rating scale for depression
16. Evidence of the dual mechanisms of action of venlafaxine
17. Is there an alternative to the randomized controlled trial?
18. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice
19. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depression
20. The treatment of chronic depression. Part 3: Psychosocial functioning before and after treatment with sertraline or imipramine
21. A new depression scale designed to be sensitive to change
22. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
23. Clinical Global Impressions
24. Neurotransmitter receptor transporter binding profile of antidepressants and their metabolites
25. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison
26. The definition and operational criteria for treatment outcome of major depressive disorder: A review of the current research literature
27. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo
28. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity
29. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
30. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study
31. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression
32. Once-daily extended release (XR) venlafaxine versus paroxetine in outpatients with major depression
33. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety
34. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients
35. How should efficacy be evaluated in randomized clinical trials of treatments for depression?
36. Relapse after cognitive behavior therapy of depression: Potential implications for longer courses of treatment
37. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
38. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice
39. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia